Details

Autor(en) / Beteiligte

• Vuijk, Stephanie A.
• Jongsma, Maria M. E.
• Hoeven, Britt M.
• Cozijnsen, Maarten A.
• Pieterson, Merel
• Meij, Tim G. J.
• Norbruis, Obbe F.
• Groeneweg, Michael
• Wolters, Victorien M.
• Wering, Herbert
• Hummel, Thalia
• Stapelbroek, Janneke
• Feen, Cathelijne
• Rheenen, Patrick F.
• Wijk, Michiel P.
• Teklenburg, Sarah
• Rizopoulos, Dimitris
• Poley, Marten J.
• Escher, Johanna C.
• Ridder, Lissy

Titel

Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease

Ist Teil von

• Alimentary pharmacology & therapeutics, 2024-06, Vol.59 (12), p.1510-1520

Ort / Verlag

England: Wiley Subscription Services, Inc

Erscheinungsjahr

2024

Quelle

Wiley Online Library All Journals

Beschreibungen/Notizen

• Summary Background Data on cost‐effectiveness of first‐line infliximab in paediatric patients with Crohn's disease are limited. Since biologics are increasingly prescribed and accompanied by high costs, this knowledge gap needs to be addressed. Aim To investigate the cost‐effectiveness of first‐line infliximab compared to conventional treatment in children with moderate‐to‐severe Crohn's disease. Methods We included patients from the Top‐down Infliximab Study in Kids with Crohn's disease randomised controlled trial. Children with newly diagnosed moderate‐to‐severe Crohn's disease were treated with azathioprine maintenance and either five induction infliximab (biosimilar) infusions or conventional induction treatment (exclusive enteral nutrition or corticosteroids). Direct healthcare consumption and costs were obtained per patient until week 104. This included data on outpatient hospital visits, hospital admissions, drug costs, endoscopies and surgeries. The primary health outcome was the odds ratio of being in clinical remission (weighted paediatric Crohn's disease activity index<12.5) during 104 weeks. Results We included 89 patients (44 in the first‐line infliximab group and 45 in the conventional treatment group). Mean direct healthcare costs per patient were €36,784 for first‐line infliximab treatment and €36,874 for conventional treatment over 2 years (p = 0.981). The odds ratio of first‐line infliximab versus conventional treatment to be in clinical remission over 104 weeks was 1.56 (95%CI 1.03–2.35, p = 0.036). Conclusions First‐line infliximab treatment resulted in higher odds of being in clinical remission without being more expensive, making it the dominant strategy over conventional treatment in the first 2 years after diagnosis in children with moderate‐to‐severe Crohn's disease. Trial registration number: NCT02517684. In children with moderate‐to‐severe Crohn's disease, first‐line infliximab treatment resulted in higher odds of being in clinical remission without being more expensive, making it the dominant strategy compared to conventional treatment in the first 2 years after diagnosis.